Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL

Clinical Trial Details

Overview

Research Study Summary

A phase 3, randomized, double blind, parallel group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses (10 and 15mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.

Purpose

The purpose of this study is to evaluate if 10 and 15mg of Lu AA21004 (the study drug) once a day compared with placebo will improve major depressive symptoms after eight weeks of treatment in patients with major depressive disorder.

Please contact Alexian Brothers for more information on participation.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 176876

Date Last Changed: July 22, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.